FDA advisers back wider access to unapproved peptides in compounding pharmacies

FDA advisers backed four unapproved peptides for use in compounding pharmacies, a move that could widen prescribing through a channel that operates with lighter oversight than traditional drugmakers. The FDA Pharmacy Compounding Advisory Committee met July 23 and July 24 in Silver Spring, Maryland, to review seven peptides and voted to support BPC-157, KPV, TB-500 and MOTS-c for the agency’s bulks list.

The decision was nonbinding and still needed FDA sign-off, but it marked a clear split with agency scientists, who opposed loosening access because the compounds’ benefits had not been demonstrated. After the first-day vote, the committee was set to review three more peptides on Friday, keeping the focus on how far compounding pharmacies should be allowed to go in making medicines that have not won full FDA approval.

For patients, the practical effect would be broader access to peptide injections made through 503A compounding pharmacies, which can prepare customized drugs from bulk ingredients under a lighter regulatory framework than the one applied to branded drugmakers. That difference matters because compounding can move products into the market faster, but without the same premarket testing that usually establishes whether a drug works and how safe it is.

The debate also reflects the way the peptide market has grown around that looser system. Compounding pharmacies have become a multibillion-dollar business, and the FDA discussion took place amid industry pressure to expand access to peptide treatments. Supporters of wider access have portrayed the drugs as useful options for patients who want or need therapies that are not sold as approved products, while critics have pointed to the lack of established evidence for some of the compounds and the quality-control questions that come with broader compounding.

The FDA panel’s vote did not settle those questions. It only moved them one step closer to the agency that will decide whether the peptides can be added to the list of substances compounding pharmacies are allowed to make.